Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CK 0803

Next Previous
Drug Profile

CK 0803

Alternative Names: CK-0803

Latest Information Update: 28 May 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cellenkos
  • Class Antiparkinsonians; T lymphocyte cell therapies
  • Mechanism of Action Regulatory T-lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Amyotrophic lateral sclerosis
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Parkinson's disease
  • No development reported Amyotrophic lateral sclerosis; Chronic inflammatory demyelinating polyradiculoneuropathy

Most Recent Events

  • 28 May 2026 No recent reports of development identified for phase-I development in Amyotrophic-lateral-sclerosis(In the elderly, In adults) in USA (IV, Infusion)
  • 20 Oct 2025 CK 0803 receives Orphan Drug status for Amyotrophic lateral sclerosis in USA
  • 20 Oct 2025 Preliminary efficacy and adverse event data from the phase Ib REGALS trial in Amyotrophic lateral sclerosis released by Cellenkos

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top